{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:02:54Z","timestamp":1789948974470,"version":"4.0.1"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe nationwide dispensing patterns of methylphenidate in Australia before and during recent prolonged supply shortages, and to assess the extent to which Section\u00a019A (S19A) overseas substitutes contributed to population\u2010level utilisation during the shortage period. Secondary aims were to compare methylphenidate dispensing with other ADHD medicines, examine changes in dispensing across individual strengths and formulations and quantify delays between S19A approval and Pharmaceutical Benefits Scheme (PBS) listing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An interrupted time series (ITS) and descriptive analysis of population\u2010level dispensing patterns was conducted using publicly available monthly dispensing data from the Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS (January 2020\u2013March 2026). Data were standardised to dispensings and defined daily doses (DDD) per 100\u2009000 population. Methylphenidate shortages were identified using the Therapeutic Goods Administration Medicines Shortages database and shortage months were designated where there was at least 1\u2009day of shortage in a month. S19A approvals, PBS listing and lapse dates were obtained from the S19A approvals database to determine delays to subsidised access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dispensing of ADHD medicines increased substantially from 2020 to 2025. Methylphenidate dispensing increased overall but plateaued from late 2024 onward, coinciding with widespread supply disruptions affecting multiple strengths and formulations. DDD ITS analysis demonstrated abrupt reductions in methylphenidate strengths (particularly 36 and 54\u2009mg) during shortages, with partial compensatory increases for some other strengths. Fifteen overseas\u2010registered methylphenidate products received S19A approval; however, of the 14 listed on the PBS, time to PBS listing ranged from 83 to 166\u2009days (median 162\u2009days). After PBS listing, S19A products contributed to 1.3% of all methylphenidate dispensings between July 2025 and March 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Methylphenidate dispensing in Australia became unstable during extensive supply shortages from late 2024. Although numerous S19A products were approved, there was minimal uptake of S19A PBS\u2010listed products at the population level. As ADHD medicine utilisation continues to rise, strengthened national strategies to improve supply chain resilience, transparency and responsiveness are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70475","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:59:54Z","timestamp":1788865194000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal Changes in Dispensing of Methylphenidate During Attention Deficit Hyperactivity Disorder Shortages in Australia: An Interrupted Time Series and Descriptive Analysis of National Dispensing Patterns"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3818-3582","authenticated-orcid":false,"given":"George","family":"Gadalla","sequence":"first","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, College of Health Adelaide University  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-4341","authenticated-orcid":false,"given":"Wern","family":"Chai","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, College of Health Adelaide University  Adelaide South Australia Australia"},{"name":"Health and Biomedical Innovation, College of Health Adelaide University  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-6128","authenticated-orcid":false,"given":"Lisa Kalisch","family":"Ellett","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, College of Health Adelaide University  Adelaide South Australia Australia"},{"name":"Quality Use of Medicines and Pharmacy Research Centre, College of Health Adelaide University  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-3504","authenticated-orcid":false,"given":"Jack","family":"Janetzki","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, College of Health Adelaide University  Adelaide South Australia Australia"},{"name":"Quality Use of Medicines and Pharmacy Research Centre, College of Health Adelaide University  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"eTG Complete","author":"Therapeutic Guidelines Limited Issuing b","year":"2003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2026.002"},{"key":"e_1_2_11_4_1","unstructured":"Australian Government Department of Health and Aged Care TGA Medicine Shortage Reports Database(2026) https:\/\/apps.tga.gov.au\/prod\/MSI\/search\/."},{"key":"e_1_2_11_5_1","unstructured":"Australian Government Department of Health and Aged Care TGA Search the Section\u00a019A Approvals Database(2026) https:\/\/www.tga.gov.au\/resources\/section\u201019a\u2010approvals."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70428"},{"key":"e_1_2_11_7_1","unstructured":"Australian Government Therapeutics Good Administration Supplying Overseas Medicines When Australian Medicines Are Unavailable or in Short Supply(2017) https:\/\/www.tga.gov.au\/resources\/guidance\/supplying\u2010overseas\u2010medicines\u2010when\u2010australian\u2010medicines\u2010are\u2010unavailable\u2010or\u2010short\u2010supply."},{"key":"e_1_2_11_8_1","unstructured":"Australian Government Department of Health DaATPBS PBS and RPBS Section\u00a085 and Section\u00a0100 Date of Supply Data(2026) https:\/\/www.pbs.gov.au\/info\/statistics\/dos\u2010and\u2010dop\/dos\u2010and\u2010dop."},{"key":"e_1_2_11_9_1","unstructured":"Australian Bureau of Statistics National State and Territory Population(2025) https:\/\/www.abs.gov.au\/statistics\/people\/population\/national\u2010state\u2010and\u2010territory\u2010population\/latest\u2010release#data\u2010downloads."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_11_11_1","unstructured":"Australian Government DoH Disability and Ageing The Pharmaceutical Benefits Scheme(2026) https:\/\/www.pbs.gov.au\/pbs\/home."},{"key":"e_1_2_11_12_1","unstructured":"Australian Government Department of Health DaATPBS Section\u00a019A Medicines Subsidised by the Pharmaceutical Benefits Scheme(2026) https:\/\/pbs.gov.au\/browse\/section\u201019a."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207338"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06199-9"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101556"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.802489"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30293-1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.48532"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70113"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-013-0106-x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215837"},{"key":"e_1_2_11_23_1","unstructured":"Australian Government Department of Health DaA Therapeutic Goods Administration Update on Methylphenidate Products Shortage: Clinical Guidance Available(2025) https:\/\/www.tga.gov.au\/safety\/shortages\u2010and\u2010supply\u2010disruptions\/medicine\u2010shortages\/medicine\u2010shortage\u2010alerts\/update\u2010methylphenidate\u2010products\u2010shortage\u2010clinical\u2010guidance\u2010available."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2025.10.008"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.101303"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100728"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(25)00194-X"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09539-x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2024.11.001"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0099"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/10870547241288351"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1529115"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1287\/msom.2023.0297"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-023-00950-6"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309992"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-026-26834-2"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","unstructured":"J.Janetzki L.Kalisch\u2010Ellett N.Pratt andA.Kemp\u2010Casey \u201cEffective Implementation of Medicines Shortage Policy: Evidence From Australia's Serious Scarcity Substitution Instruments \u201d medRxiv 2026.2002.2002.26345406(2026).","DOI":"10.64898\/2026.02.02.26345406"},{"key":"e_1_2_11_38_1","unstructured":"B. C.Tom HardyandY.Yu Evolving Beyond the PBS: Exploring Australia's Private Medicines Market(2025) https:\/\/www.iqvia.com\/locations\/australia\u2010and\u2010new\u2010zealand\/library\/white\u2010papers\/evolving\u2010beyond\u2010the\u2010pbs."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:54:44Z","timestamp":1789948484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/pds.70475"],"URL":"https:\/\/doi.org\/10.1002\/pds.70475","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70475"}}